| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
University of Pittsburgh Cancer Institute, [B. R. K., T-S. T. N., R. S. D.], Departments of Urology [B. R. K., R. H. G.], Pathology [R. D., M. J. B., R. H. G.], and Pharmacology [R. D., M. J. B., R. H. G.], University of Pittsburgh School of Medicine [R. H. G.], Pittsburgh, Pennsylvania 15213-2582, and Departments of Medicine and Surgery, University of Chicago, Chicago, Illinois 60637 [W. M. S., R. H. G.]
We have identified previously six nuclear matrix proteins (NMPs) that are bladder cancer specific. In this study, we analyzed the expression of one of these proteins, BLCA-4, in bladder tumors and normal bladder tissue. We also examined the appearance of BLCA-4 in the urine as a biomarker for bladder cancer. BLCA-4 was isolated from nuclear matrix preparations of bladder tumors, and its peptide sequence was determined. The antibodies generated against the resulting BLCA-4 peptides were then used to detect its presence in immunoblots and in urine samples by immunoassay. We analyzed tissue samples of bladder tumor and normal donor bladders and urine obtained from 51 normal individuals and 54 patients with pathologically confirmed bladder cancer. The BLCA-4 peptide sequences do not resemble any known human protein sequences. On immunoblot analysis, BLCA-4 expression was detectable in tumor and normal tissues from patients with bladder cancer but not in any of the normal bladder tissue obtained from organ donors. Using a prospectively determined cutoff level of 13 A (absorbance) units/µg protein, all 51 normal individuals tested were negative for BLCA-4 expression, whereas 53 of 55 samples from patients with bladder cancer were positive. These results suggest that BLCA-4 is present throughout the bladder in both the tumor and morphologically normal areas in bladder cancer patients. BLCA-4 is a very sensitive (96.4%) and specific (100%) marker for bladder cancer. BLCA-4 is a bladder cancer-specific marker that can be detected using a urine-based assay and can be used in the diagnosis of bladder cancer.
This article has been cited by other articles:
|
|
 |
|
  J. M. Myers-Irvin, T.-S. Van Le, and R. H. Getzenberg Mechanistic Analysis of the Role of BLCA-4 in Bladder Cancer Pathobiology Cancer Res., August 15, 2005; 65(16): 7145 - 7150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Paul, R. Dhir, D. Landsittel, M. R. Hitchens, and R. H. Getzenberg Detection of Prostate Cancer with a Blood-Based Assay for Early Prostate Cancer Antigen Cancer Res., May 15, 2005; 65(10): 4097 - 4100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-S. Van Le, J. Myers, B. R. Konety, T. Barder, and R. H. Getzenberg Functional Characterization of the Bladder Cancer Marker, BLCA-4 Clin. Cancer Res., February 15, 2004; 10(4): 1384 - 1391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sanchez-Carbayo Use of High-Throughput DNA Microarrays to Identify Biomarkers for Bladder Cancer Clin. Chem., January 1, 2003; 49(1): 23 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Coffey Nuclear Matrix Proteins as Proteomic Markers of Preneoplastic and Cancer Lesions : Commentary re: G. Brunagel et al., Nuclear Matrix Protein Alterations Associated with Colon Cancer Metastasis to the Liver. Clin. Cancer Res., 8: 3039-3045, 2002. Clin. Cancer Res., October 1, 2002; 8(10): 3031 - 3033. [Full Text] [PDF]
|
|
|
|
|
|
G. Brunagel, B. N. Vietmeier, A. J. Bauer, R. E. Schoen, and R. H. Getzenberg Identification of Nuclear Matrix Protein Alterations Associated with Human Colon Cancer Cancer Res., April 1, 2002; 62(8): 2437 - 2442. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
